Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VMn-Gd is an experimental **virus-like hollow bimetallic manganese-gadolinium nanoparticle** developed as a tumor-microenvironment-responsive nanomedicine platform. Under acidic tumor conditions, the Mn-Gd structure degrades and releases manganese and gadolinium species; manganese-mediated glutathione depletion and Fenton-like reactive-oxygen-species generation can enhance oxidative damage, while gadolinium contributes X-ray attenuation and radiosensitization. VMn-Gd also has T1-weighted magnetic-resonance contrast potential. It is the nanoparticle core used to construct the more complex VMn-Gd@GOx-EVs system, which additionally incorporates glucose oxidase and extracellular-vesicle coating for breast-cancer targeting and combined oxidative therapy with radiotherapy. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12337444/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VMn-Gd.